|
1
|
Chavan S, Bray F, Lortet-Tieulent J,
Goodman M and Jemal A: International variations in bladder cancer
incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: A
combined analysis of 2596 patients from seven EORTC trials. Eur
Urol. 49:466–477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shariat SF, Karakiewicz PI, Palapattu GS,
Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ,
Sagalowsky AI, et al: Outcomes of radical cystectomy for
transitional cell carcinoma of the bladder: A contemporary series
from the Bladder Cancer Research Consortium. J Urol. 176(6 Pt 1):
2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tilki D, Reich O, Karakiewicz PI, Novara
G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG,
et al: Validation of the AJCC TNM substaging of pT2 bladder cancer:
Deep muscle invasion is associated with significantly worse
outcome. Eur Urol. 58:112–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JY, Yun SJ, Jeong P, Piao XM, Kim YH,
Kim J, Subramaniyam S, Byun YJ, Kang HW, Seo SP, et al:
Identification of differentially expressed miRNAs and
miRNA-targeted genes in bladder cancer. Oncotarget. 9:27656–27666.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Piao XM, Jeong P, Kim YH, Byun YJ, Xu Y,
Kang HW, Ha YS, Kim WT, Lee JY, Woo SH, et al: Urinary cell-free
microRNA biomarker could discriminate bladder cancer from benign
hematuria. Int J Cancer. 144:380–388. 2019. View Article : Google Scholar
|
|
8
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Venning FA, Wullkopf L and Erler JT:
Targeting ECM disrupts cancer progression. Front Oncol. 5:2242015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levental KR, Yu H, Kass L, Lakins JN,
Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et
al: Matrix crosslinking forces tumor progression by enhancing
integrin signaling. Cell. 139:891–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arnold SA, Rivera LB, Miller AF, Carbon
JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P,
Bradshaw AD and Brekken RA: Lack of host SPARC enhances vascular
function and tumor spread in an orthotopic murine model of
pancreatic carcinoma. Dis Models Mech. 3:57–72. 2010. View Article : Google Scholar
|
|
12
|
Aitken KJ and Bägli DJ: The bladder
extracellular matrix. Part I: Architecture, development and
disease. Nat Rev Urol. 6:596–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cescon M, Gattazzo F, Chen P and Bonaldo
P: Collagen VI at a glance. J Cell Sci. 128:3525–3531. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan F, Wang H, Shen Y, Zhang H, Shi G, Zhu
Y, Dai B and Ye D: Upregulation of COL6A1 is predictive of poor
prognosis in clear cell renal cell carcinoma patients. Oncotarget.
6:27378–27387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu YP, Wan FN, Shen YJ, Wang HK, Zhang GM
and Ye DW: Reactive stroma component COL6A1 is upregulated in
castration-resistant prostate cancer and promotes tumor growth.
Oncotarget. 6:14488–14496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hou T, Tong C, Kazobinka G, Zhang W, Huang
X, Huang Y and Zhang Y: Expression of COL6A1 predicts prognosis in
cervical cancer patients. Am J Transl Res. 8:2838–2844.
2016.PubMed/NCBI
|
|
17
|
Chiu KH, Chang YH, Wu YS, Lee SH and Liao
PC: Quantitative secretome analysis reveals that COL6A1 is a
metastasis-associated protein using stacking gel-aided purification
combined with iTRAQ labeling. J Proteome Res. 10:1110–1125. 2011.
View Article : Google Scholar
|
|
18
|
Stone R II, Sabichi AL, Gill J, Lee IL,
Adegboyega P, Dai MS, Loganantharaj R, Trutschl M, Cvek U and
Clifford JL: Identification of genes correlated with early-stage
bladder cancer progression. Cancer Prev Res (Phila). 3:776–786.
2010. View Article : Google Scholar :
|
|
19
|
Shi S and Tian B: Identification of
biomarkers associated with progression and prognosis in bladder
cancer via co-expression analysis. Cancer Biomark. 24:183–193.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu H, Chen H, Wang J, Zhou L and Liu S:
Collagen stiffness promoted non-muscle-invasive bladder cancer
progression to muscle-invasive bladder cancer. OncoTargets Ther.
12:3441–3457. 2019. View Article : Google Scholar
|
|
21
|
Oosterlinck W, Lobel B, Jakse G, Malmström
PU, Stöckle M and Sternberg C; European Association of Urology
(EAU) Working Group on Oncological Urology: Guidelines on bladder
cancer. Eur Urol. 41:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A;
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alfred Witjes J, Lebret T, Compérat EM,
Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinós EL, Dunn J,
Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive
and metastatic bladder cancer. Eur Urol. 71:462–475. 2017.
View Article : Google Scholar
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Yun SJ, Jeong P, Kang HW, Kim YH, Kim EA
and Yan C: Urinary MicroRNAs of prostate cancer: Virus-Encoded
hsv1-miRH18 and hsv2-miR-H9-5p could be valuable diagnostic
markers. Int Neurourol J. 19:74–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiang M, Zeng Y, Yang R, Xu H, Chen Z,
Zhong J, Xie H, Xu Y and Zeng X: U6 is not a suitable endogenous
control for the quantification of circulating microRNAs. Biochem
Biophys Res Commun. 454:210–214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47(D1): D607–D613. 2019.
View Article : Google Scholar
|
|
28
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar
|
|
29
|
Chen P, Cescon M and Bonaldo P: Collagen
VI in cancer and its biological mechanisms. Trends Mol Med.
19:410–417. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jin Z, Yao J, Xie N, Cai L, Qi S, Zhang Z
and Li B: Melittin constrains the expression of identified key
genes associated with bladder cancer. J Immunol Res.
2018:50381722018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang M, Yuan J, Peng C and Li Y: Collagen
as a double-edged sword in tumor progression. Tumor Biol.
35:2871–2882. 2014. View Article : Google Scholar
|
|
32
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jeggo PA, Pearl LH and Carr AM: DNA
repair, genome stability and cancer: A historical perspective. Nat
Rev Cancer. 16:35–42. 2016. View Article : Google Scholar
|
|
34
|
Shamloo B and Usluer S: p21 in cancer
research. Cancers. 11:11782019. View Article : Google Scholar :
|
|
35
|
Donjerkovic D and Scott DW: Regulation of
the G1 phase of the mammalian cell cycle. Cell Res. 10:1–16. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kamiyama M, Naguro I and Ichijo H: In vivo
gene manipulation reveals the impact of stress-responsive MAPK
pathways on tumor progression. Cancer Sci. 106:785–796. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH
and Hung MC: Cytoplasmic localization of p21 Cip1/WAF1 by
Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat
Cell Biol. 3:245–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kumar B, Koul S, Petersen J, Khandrika L,
Hwa JS, Meacham RB, Wilson S and Koul HK: p38 mitogen-activated
protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer
by modulation of MMP-2 and MMP-9 activity. Cancer Res. 70:832–841.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chetty C, Lakka SS, Bhoopathi P and Rao
JS: MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated
PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer.
127:1081–1095. 2010. View Article : Google Scholar :
|
|
42
|
Giannı̀ M, Kopf E, Bastien J,
Oulad-Abdelghani M, Garattini E, Chambon P and Rochette-Egly C:
Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is
involved in retinoic acid-induced phosphorylation, degradation, and
transcriptional activity of retinoic acid receptor gamma 2. J Biol
Chem. 277:24859–24862. 2002. View Article : Google Scholar
|
|
43
|
Liu W, Ding I, Chen K, Olschowka J, Xu J,
Hu D, Morrow GR and Okunieff P: Interleukin 1beta (IL1B) signaling
is a critical component of radiation-induced skin fibrosis. Radiat
Res. 165:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang F, Tang J, Li P, Si S, Yu H, Yang X,
Tao J, Lv Q, Gu M, Yang H and Wang Z: Chloroquine enhances the
radiosensitivity of bladder cancer cells by inhibiting autophagy
and activating apoptosis. Cell Physiol Biochem. 45:54–66. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Devanand P, Kim SI, Choi YW, Sheen SS, Yim
H, Ryu MS, Kim SJ, Kim WJ and Lim IK: Inhibition of bladder cancer
invasion by Sp1-mediated BTG2 expression via inhibition of DNA
methyltransferase 1. FEBS J. 281:5581–5601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu D, Tao J, Xu B, Qing W, Li P, Lu Q and
Zhang W: Phosphatidylinositol 3-kinase inhibitor LY294002
suppresses proliferation and sensitizes doxorubicin chemotherapy in
bladder cancer cells. Urol Int. 86:346–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wahafu W, Gai J, Song L, Ping H, Wang M,
Yang F, Niu Y and Xing N: Increased H2S and its
synthases in urothelial cell carcinoma of the bladder, and enhanced
cisplatin-induced apoptosis following H2S inhibition in
EJ cells. Oncol Lett. 15:8484–8490. 2018.PubMed/NCBI
|
|
48
|
Silvers CR, Liu YR, Wu CH, Miyamoto H,
Messing EM and Lee YF: Identification of extracellular
vesicle-borne periostin as a feature of muscle-invasive bladder
cancer. Oncotarget. 7:23335–23345. 2016. View Article : Google Scholar : PubMed/NCBI
|
